Interleukin-2
Interleukin-2 is a pharmaceutical drug with 147 clinical trials. Currently 33 active trials ongoing. Historical success rate of 72.0%.
Success Metrics
Based on 59 completed trials
Phase Distribution
Phase Distribution
70
Early Stage
59
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
67.8%
59 of 87 finished
32.2%
28 ended early
33
trials recruiting
147
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Therapy for Children With Advanced Stage Neuroblastoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Clinical Trials (147)
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Therapy for Children With Advanced Stage Neuroblastoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
CIML NK Cells With Venetoclax for AML
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
TIL Therapy in cSCC and MCC
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 147